Workflow
济民医疗(603222) - 2024 Q4 - 年度业绩预告
ChiminChimin(SH:603222)2025-04-18 08:05

Financial Performance - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between -62 million and -52 million yuan, a reduction in losses compared to -65.48 million yuan in the same period last year [2]. - The estimated net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is also projected to be between -62 million and -52 million yuan for 2024 [4]. - The company reported a net profit of -65.48 million yuan for the same period last year, with a net profit excluding non-recurring gains and losses of -67.80 million yuan [5]. Loss Recognition - The company has recognized potential losses of approximately 30 million yuan related to the case of forgery involving company seals, along with an additional 8 million yuan for inventory impairment [7]. - The company has estimated a loss of approximately 2 million yuan due to the illegal appropriation of inventory by the former vice president and his team [7]. Investigations and Impact - The previous sales target for 2025 has been revised due to the ongoing investigation and its impact on future sales [6]. - The company has taken measures to address the situation, including reporting the case to the police and forming a special task force with external legal teams [6]. - The company emphasizes the importance of cautious and reasonable assessments of the impact on its performance due to the ongoing investigation [9]. Apology and Financial Data - The company has issued an apology to investors for the impact of the profit warning correction [9]. - The financial data provided is preliminary and subject to final audit confirmation in the 2024 annual report [8].